Allison Mo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Allison Mo has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Zoe K. McQuilten
Monash University
7 shared publications - Erica M. Wood
School of Public Health and Preventive Medicine Monash University Melbourne Victoria Australia
5 shared publications - Jake Shortt
Monash University
4 shared publications Jake Shortt
Monash Hematology, Monash Health Melbourne Australia
3 shared publicationsAbbey Willcox
Australian Centre for Blood Diseases, Monash University Melbourne Victoria Australia
2 shared publicationsCarole Smith
Department of Haematology, Dorevitch Pathology Melbourne Victoria Australia
2 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Wiley in Transfusion
- Vol. 66 (10) , 1939-1951
Monitoring and feedback using data in transfusion medicine: A study of practices from the BEST Collaborative
Background: It is imperative that health systems monitor transfusion practice quality and implement improvements when evidence‐based practice gaps are identified. Despite the importance of data‐driven quality activities, little is known about approaches employed by hospitals. This study aimed to describe strategies used by hospitals to acquire, analyze, and apply transfusion‐related quality data. Study Design and Methods: A pre‐piloted survey was developed by the core team, and Biomedical Excellence for Safer Transfusion (BEST) Collaborative attendees of meetings were invited to participate. Topics spanned five domains: hospital characteristics, data acquisition, quality metric prioritization, data analysis/visualization, and feedback processes. Responses were summarized to identify patterns and variation across institutions. Results: Nine hospitals of varying size, specialty mix, and transfusion volumes from three continents participated. Most transfusion services acquired transfusion data from both the electronic health record and the laboratory information system (6/9, 67%). Although all sites tracked the number of transfusions, there was wide variation in other metrics prioritized. Transfusion appropriateness was prioritized by 7 of 9 centers, but few reported monitoring antifibrinolytic agent use (2/9, 22%), anemia management (4/9, 44%), and consent (2/9, 22%). All hospitals performed some form of data analysis, but chart/table types and functionalities differed. Feedback was typically provided by transfusion medicine specialists or hematology, but frequency and means differed between sites. Discussion: This descriptive study highlights significant variation in how selected hospitals use data to monitor transfusion practices and provide feedback. There are many opportunities to enhance optimal uses of data to deliver effective quality improvement.
- 22 June 2026
- Published by Wiley in Transfusion
- Vol. 66 (10) , 1939-1951
Open AccessMonitoring and feedback using data in transfusion medicine: A study of practices from the BEST Collaborative
Background: It is imperative that health systems monitor transfusion practice quality and implement improvements when evidence‐based practice gaps are identified. Despite the importance of data‐driven quality activities, little is known about approaches employed by hospitals. This study aimed to describe strategies used by hospitals to acquire, analyze, and apply transfusion‐related quality data. Study Design and Methods: A pre‐piloted survey was developed by the core team, and Biomedical Excellence for Safer Transfusion (BEST) Collaborative attendees of meetings were invited to participate. Topics spanned five domains: hospital characteristics, data acquisition, quality metric prioritization, data analysis/visualization, and feedback processes. Responses were summarized to identify patterns and variation across institutions. Results: Nine hospitals of varying size, specialty mix, and transfusion volumes from three continents participated. Most transfusion services acquired transfusion data from both the electronic health record and the laboratory information system (6/9, 67%). Although all sites tracked the number of transfusions, there was wide variation in other metrics prioritized. Transfusion appropriateness was prioritized by 7 of 9 centers, but few reported monitoring antifibrinolytic agent use (2/9, 22%), anemia management (4/9, 44%), and consent (2/9, 22%). All hospitals performed some form of data analysis, but chart/table types and functionalities differed. Feedback was typically provided by transfusion medicine specialists or hematology, but frequency and means differed between sites. Discussion: This descriptive study highlights significant variation in how selected hospitals use data to monitor transfusion practices and provide feedback. There are many opportunities to enhance optimal uses of data to deliver effective quality improvement.
- Open Access
- 31 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 1007-1015
Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study
Background: Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines were published. Aims: Describe red blood cell transfusion (RBC‐T) and platelet transfusion (PLT‐T) burden in MDS/CMML and any changes since 2011. Method: Retrospective longitudinal cohort study of all MDS/CMML patients in the state of Victoria (population 6.5 million) from 2009 to 2022, linking hospital admissions dataset, cancer and death registries. Results: 7043 patients (5715 MDS; 1328 CMML), with median follow‐up 1.8 years (interquartile range [IQR]: 0.5–4.0 years), had 55 048 RBC‐T and 10 749 PLT‐T episodes. By 5 years post‐diagnosis, patients had on average 14 RBC‐T and 3 PLT‐T admissions, with transfusion burden affected by MDS subtype. PLT‐T were significantly higher post‐2011 versus pre‐2011 (0.8 more PLT‐T admissions by 2 years, p < 0.001), with no difference in RBC‐T admissions. Conclusion: Since 2011, RBC‐T burden has remained stable, but PLT‐Ts have increased. Given the potential costs and limited PLT inventories, this impacts blood supply planning and highlights the need for research to optimise PLT‐T in MDS/CMML patients.
- 31 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 1007-1015
Open AccessLongitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study
Background: Real‐world data on transfusion needs of patients with myelodysplastic syndromes (MDS), and the impacts of disease‐modifying therapies (DMTs) are sparse. In 2011, 5‐azacitidine became the first funded DMT for MDS and chronic myelomonocytic leukaemia (CMML) patients in Australia and national patient blood management (PBM) guidelines were published. Aims: Describe red blood cell transfusion (RBC‐T) and platelet transfusion (PLT‐T) burden in MDS/CMML and any changes since 2011. Method: Retrospective longitudinal cohort study of all MDS/CMML patients in the state of Victoria (population 6.5 million) from 2009 to 2022, linking hospital admissions dataset, cancer and death registries. Results: 7043 patients (5715 MDS; 1328 CMML), with median follow‐up 1.8 years (interquartile range [IQR]: 0.5–4.0 years), had 55 048 RBC‐T and 10 749 PLT‐T episodes. By 5 years post‐diagnosis, patients had on average 14 RBC‐T and 3 PLT‐T admissions, with transfusion burden affected by MDS subtype. PLT‐T were significantly higher post‐2011 versus pre‐2011 (0.8 more PLT‐T admissions by 2 years, p < 0.001), with no difference in RBC‐T admissions. Conclusion: Since 2011, RBC‐T burden has remained stable, but PLT‐Ts have increased. Given the potential costs and limited PLT inventories, this impacts blood supply planning and highlights the need for research to optimise PLT‐T in MDS/CMML patients.
- Open Access
- 21 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 275-285
The true cost of red cell transfusion for patients with myelodysplastic syndromes: A time‐driven activity‐based costing study
Summary: Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital. Every activity relating to RBC transfusion in patients with MDS was observed and process‐mapped, ranging from patient pre‐transfusion phlebotomy through to laboratory processes, clinical transfusion in inpatient and outpatient wards, clinical follow‐up and transfusion governance and oversight. For each activity, detailed data collection was undertaken, including timing of individual steps and recording all consumables, equipment and personnel involved. The total per‐unit cost was US$440.47, with an annual per‐patient estimated cost of US$6607.12. Hospital‐related costs contributed 41% of the total cost, with the largest contributor being equipment (16%) followed by staffing (14%). Alloimmunisation increased process costs by 24%. These findings demonstrate that hospital process costs need to be included when considering and budgeting for the total cost of the transfusion process. Our findings will inform future transfusion‐related resourcing and cost‐effectiveness evaluations of treatments which aim to reduce RBC transfusion burden and improve quality of life in MDS.
- 21 May 2026
- Published by Wiley in British Journal of Haematology
- Vol. 209 (1) , 275-285
Open AccessThe true cost of red cell transfusion for patients with myelodysplastic syndromes: A time‐driven activity‐based costing study
Summary: Patients with myelodysplastic syndromes (MDS) often require red blood cell (RBC) transfusion. However, the true cost of RBC transfusion, beyond the acquisition cost of the unit, is poorly defined. We conducted a prospective time‐driven activity‐based costing study at a large Australian university teaching hospital. Every activity relating to RBC transfusion in patients with MDS was observed and process‐mapped, ranging from patient pre‐transfusion phlebotomy through to laboratory processes, clinical transfusion in inpatient and outpatient wards, clinical follow‐up and transfusion governance and oversight. For each activity, detailed data collection was undertaken, including timing of individual steps and recording all consumables, equipment and personnel involved. The total per‐unit cost was US$440.47, with an annual per‐patient estimated cost of US$6607.12. Hospital‐related costs contributed 41% of the total cost, with the largest contributor being equipment (16%) followed by staffing (14%). Alloimmunisation increased process costs by 24%. These findings demonstrate that hospital process costs need to be included when considering and budgeting for the total cost of the transfusion process. Our findings will inform future transfusion‐related resourcing and cost‐effectiveness evaluations of treatments which aim to reduce RBC transfusion burden and improve quality of life in MDS.
- Open Access
- 29 August 2025
- Published by Wiley in Transfusion
- Vol. 65 (10) , 1803-1809
Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes
Background: Evidence guiding optimal transfusion practice for patients with myelodysplastic syndromes (MDS) is lacking. Many patients have concurrent cardiac disease. Data on practice are sparse. We aimed to describe the use of red blood cell (RBC) transfusion and the prevalence of cardiac comorbidities in patients with MDS within Australia's largest public hospital network to better understand real‐world practices and outcomes. Methods: We conducted a retrospective cohort study of patients aged ≥18 years with MDS, MDS/myeloproliferative overlap neoplasm or chronic myelomonocytic leukemia admitted from 2016 to 2018 to determine RBC transfusion‐related endpoints. Results: One hundred and seventy‐nine patients (median age 78 years, 61.5% male) were included, with a median follow‐up of 46 weeks. Of these, 102 (57.0%) received RBC transfusion. Transfused patients had lower presenting Hb (87 vs. 105 g/L, p < 0.0001), higher rates of cardiac disease (29.4% vs. 12.9%, p = 0.009) and 5‐azacytidine use (31.4% vs. 13.0%, p = 0.004). Sixty‐five patients (36.3%) received outpatient RBC transfusions, with a median of 2 units RBC per transfusion and 14 days between transfusions. The median pre‐transfusion Hb was 80 g/L (IQR 74–86 g/L). Forty patients (22.4%) had evidence of cardiac disease, with similar pre‐transfusion Hb for patients with and without cardiac disease (median Hb 79 g/L vs. 81 g/L, p = 0.1). Discussion: Patients with MDS frequently require RBC transfusion, and restrictive transfusion strategies predominate despite many patients having cardiac comorbidities. Further research is needed to address optimal transfusion strategies in such patients and associated cardiac outcomes.
- 29 August 2025
- Published by Wiley in Transfusion
- Vol. 65 (10) , 1803-1809
Open AccessRed blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes
Background: Evidence guiding optimal transfusion practice for patients with myelodysplastic syndromes (MDS) is lacking. Many patients have concurrent cardiac disease. Data on practice are sparse. We aimed to describe the use of red blood cell (RBC) transfusion and the prevalence of cardiac comorbidities in patients with MDS within Australia's largest public hospital network to better understand real‐world practices and outcomes. Methods: We conducted a retrospective cohort study of patients aged ≥18 years with MDS, MDS/myeloproliferative overlap neoplasm or chronic myelomonocytic leukemia admitted from 2016 to 2018 to determine RBC transfusion‐related endpoints. Results: One hundred and seventy‐nine patients (median age 78 years, 61.5% male) were included, with a median follow‐up of 46 weeks. Of these, 102 (57.0%) received RBC transfusion. Transfused patients had lower presenting Hb (87 vs. 105 g/L, p < 0.0001), higher rates of cardiac disease (29.4% vs. 12.9%, p = 0.009) and 5‐azacytidine use (31.4% vs. 13.0%, p = 0.004). Sixty‐five patients (36.3%) received outpatient RBC transfusions, with a median of 2 units RBC per transfusion and 14 days between transfusions. The median pre‐transfusion Hb was 80 g/L (IQR 74–86 g/L). Forty patients (22.4%) had evidence of cardiac disease, with similar pre‐transfusion Hb for patients with and without cardiac disease (median Hb 79 g/L vs. 81 g/L, p = 0.1). Discussion: Patients with MDS frequently require RBC transfusion, and restrictive transfusion strategies predominate despite many patients having cardiac comorbidities. Further research is needed to address optimal transfusion strategies in such patients and associated cardiac outcomes.
- 28 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1602-1604
The importance of ABO in platelet refractoriness, an often overlooked option
ABO‐non‐identical (ni) platelets provide less of an increase in platelet count and may increase the length of patient transfusions. The paper by Han and Badami showed that ABO‐ni platelets may be a risk factor for immune platelet transfusion refractoriness.Commentary on: Han et al. ABO non‐identical platelet transfusions, immune platelet refractoriness and platelet support. Br J Haematol 2024;204:2097‐2102.
- 28 March 2024
- Published by Wiley in British Journal of Haematology
- Vol. 204 (5) , 1602-1604
The importance of ABO in platelet refractoriness, an often overlooked option
ABO‐non‐identical (ni) platelets provide less of an increase in platelet count and may increase the length of patient transfusions. The paper by Han and Badami showed that ABO‐ni platelets may be a risk factor for immune platelet transfusion refractoriness.Commentary on: Han et al. ABO non‐identical platelet transfusions, immune platelet refractoriness and platelet support. Br J Haematol 2024;204:2097‐2102.
- Open Access
- 12 January 2024
- Published by Wiley in Transfusion
- Vol. 64 (2) , 236-247
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes
Background: Anemia in myelodysplastic syndromes (MDS) is associated with poorer health‐related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2–4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low‐dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes.Study Design and Methods: In this n‐of‐1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended‐matched RBCs are provided, with transfusion based upon the previous week's Hb/pre‐transfusion testing results to eliminate delays of awaiting contemporaneous cross‐matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences.Results: The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter‐country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units.Discussion: This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre‐transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.
- 12 January 2024
- Published by Wiley in Transfusion
- Vol. 64 (2) , 236-247
Open AccessRethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes
Background: Anemia in myelodysplastic syndromes (MDS) is associated with poorer health‐related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple red blood cells (RBC) units every 2–4 weeks may result in peaks/troughs in hemoglobin (Hb) level, yet maintaining a stable Hb may better improve HRQoL. We describe a study protocol aiming to investigate the feasibility of weekly low‐dose RBC transfusion in MDS patients, including assessing HRQoL and physical function outcomes.Study Design and Methods: In this n‐of‐1 pilot study, patients receive two treatment arms, with randomly allocated treatment sequence: arm A (patient's usual transfusion schedule) and arm B (weekly transfusion, individualized per patient). To facilitate timely delivery of weekly transfusion, extended‐matched RBCs are provided, with transfusion based upon the previous week's Hb/pre‐transfusion testing results to eliminate delays of awaiting contemporaneous cross‐matching. Primary outcome is the feasibility of delivering weekly transfusion. Secondary outcomes include HRQoL, functional activity measurements, RBC usage, and alloimmunization rates. A qualitative substudy explores patient and staff experiences.Results: The trial is open in Australia, Netherlands, and UK. The first patient was recruited in 2020. Inter‐country differences in providing RBCs are observed, including patient genotyping versus serological phenotyping to select compatible units.Discussion: This pilot trial evaluates a novel personalized transfusion approach of weekly matched RBC transfusion and challenges the dogma of current routine pre‐transfusion matching practice. Findings on study feasibility, HRQoL, and physical functional outcomes and the qualitative substudy will inform the design of a larger definitive trial powered for clinical outcomes.
- Open Access
- 20 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 621-626
Use of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey
Aim: Thrombocytopenia and bleeding are common in myelodysplastic syndromes (MDS), but optimal management is unknown. We conducted a survey to identify current clinical practice regarding platelet transfusion (PLT‐T) and tranexamic acid (TXA) to inform future trial design.Method: A 25‐question survey was distributed to members of the ALLG from December 2020 to July 2021.Results: Sixty‐four clinicians across Australia, New Zealand and Singapore responded. Clinicians treated a median of 15 MDS patients annually. Twenty‐nine (45%) reported having institutional guidelines regarding prophylactic PLT‐T. Although 60 (94%) said they would consider using TXA, most (58/64; 91%) did not have institutional guidelines. Clinical scenarios showed prophylactic PLT‐T was more likely administered for patients on disease‐modifying therapy (49/64; 76%, commonest threshold 9/L) or with minor bleeding (32/64 [50%] transfusing at threshold 9/L, 23/64 [35%] at 9/L). For stable untreated patients, 29/64 (45%) would not give PLT‐T and 32/64 (50%) would. Most respondents (46/64; 72%) were interested in participating in trials in this area. Potential barriers included resource limitations, funding and patient/clinician acceptance.Conclusion: Real‐world management of MDS‐related thrombocytopenia varies and there is a need for clinical trials to inform practice.
- 20 December 2023
- Published by Wiley in European Journal of Haematology
- Vol. 112 (4) , 621-626
Open AccessUse of platelet transfusions and tranexamic acid in patients with myelodysplastic syndromes: A clinical practice survey
Aim: Thrombocytopenia and bleeding are common in myelodysplastic syndromes (MDS), but optimal management is unknown. We conducted a survey to identify current clinical practice regarding platelet transfusion (PLT‐T) and tranexamic acid (TXA) to inform future trial design.Method: A 25‐question survey was distributed to members of the ALLG from December 2020 to July 2021.Results: Sixty‐four clinicians across Australia, New Zealand and Singapore responded. Clinicians treated a median of 15 MDS patients annually. Twenty‐nine (45%) reported having institutional guidelines regarding prophylactic PLT‐T. Although 60 (94%) said they would consider using TXA, most (58/64; 91%) did not have institutional guidelines. Clinical scenarios showed prophylactic PLT‐T was more likely administered for patients on disease‐modifying therapy (49/64; 76%, commonest threshold 9/L) or with minor bleeding (32/64 [50%] transfusing at threshold 9/L, 23/64 [35%] at 9/L). For stable untreated patients, 29/64 (45%) would not give PLT‐T and 32/64 (50%) would. Most respondents (46/64; 72%) were interested in participating in trials in this area. Potential barriers included resource limitations, funding and patient/clinician acceptance.Conclusion: Real‐world management of MDS‐related thrombocytopenia varies and there is a need for clinical trials to inform practice.
- Open Access
- 15 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 592-600
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes
Objectives: This study aimed to describe the burden of thrombocytopenia, supportive care practices, bleeding complications and predictors of bleeding in MDS patients within a large Australian hospital network, to better understand the use and effectiveness of platelet transfusions in MDS.Methods: A retrospective cohort study of patients aged ≥18 years with MDS, chronic myelomonocytic leukaemia or MDS/myeloproliferative overlap neoplasm admitted from 2016 to 2018 was conducted. Data were obtained from hospital medical records.Results: One hundred seventy‐nine patients (median age 78 years, 61.5% male) were identified. The median platelet count at first admission was 90 × 109/L. Twenty‐eight (15.6%) patients had severe thrombocytopenia (platelet count 9/L), of whom nine (32.1%) received prophylactic platelet transfusions, five (17.9%) received tranexamic acid (TXA), seven (25%) received both platelet transfusions and TXA, and seven (25%) received no treatment. Bleeding events requiring hospitalisation occurred in 20 (11.2%) patients. Bleeding was not predicted by presenting platelet count, TXA use, platelet transfusion or anticoagulant/antiplatelet therapies. Three patients died of bleeding, at varying platelet counts (18, 38 and 153 × 109/L).Conclusion: Thrombocytopenia is common in MDS. Although guidelines recommend otherwise, prophylactic platelet transfusions were commonly used for severe thrombocytopenia. Despite the majority of patients receiving platelet transfusions and/or TXA, 11% developed major bleeding occurring at a wide range of platelet counts.
- 15 July 2023
- Published by Wiley in European Journal of Haematology
- Vol. 111 (4) , 592-600
Open AccessPlatelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes
Objectives: This study aimed to describe the burden of thrombocytopenia, supportive care practices, bleeding complications and predictors of bleeding in MDS patients within a large Australian hospital network, to better understand the use and effectiveness of platelet transfusions in MDS.Methods: A retrospective cohort study of patients aged ≥18 years with MDS, chronic myelomonocytic leukaemia or MDS/myeloproliferative overlap neoplasm admitted from 2016 to 2018 was conducted. Data were obtained from hospital medical records.Results: One hundred seventy‐nine patients (median age 78 years, 61.5% male) were identified. The median platelet count at first admission was 90 × 109/L. Twenty‐eight (15.6%) patients had severe thrombocytopenia (platelet count 9/L), of whom nine (32.1%) received prophylactic platelet transfusions, five (17.9%) received tranexamic acid (TXA), seven (25%) received both platelet transfusions and TXA, and seven (25%) received no treatment. Bleeding events requiring hospitalisation occurred in 20 (11.2%) patients. Bleeding was not predicted by presenting platelet count, TXA use, platelet transfusion or anticoagulant/antiplatelet therapies. Three patients died of bleeding, at varying platelet counts (18, 38 and 153 × 109/L).Conclusion: Thrombocytopenia is common in MDS. Although guidelines recommend otherwise, prophylactic platelet transfusions were commonly used for severe thrombocytopenia. Despite the majority of patients receiving platelet transfusions and/or TXA, 11% developed major bleeding occurring at a wide range of platelet counts.
- 19 September 2022
- Published by Wiley in Transfusion
- Vol. 62 (10) , 1929-1932
Restrictive transfusion thresholds: Have we left patient‐centered outcomes behind?
See article on page 1973–1983, in this issue
- 19 September 2022
- Published by Wiley in Transfusion
- Vol. 62 (10) , 1929-1932
Restrictive transfusion thresholds: Have we left patient‐centered outcomes behind?
See article on page 1973–1983, in this issue
- 1 June 2021
- Published by Wiley in Transfusion
- Vol. 61 (7) , 2195-2203
Red cell transfusions: Is less always best?
- 1 June 2021
- Published by Wiley in Transfusion
- Vol. 61 (7) , 2195-2203
Red cell transfusions: Is less always best?